TQT
Showing 1 - 25 of 54
Healthy Subject Trial in Beijing (Orelabrutinib and (orelabrutinib tablet simulator), Orelabrutinib, Placebo (orelabrutinib
Active, not recruiting
- Healthy Subject
- Orelabrutinib and placebo (orelabrutinib tablet simulator)
- +3 more
-
Beijing, ChinaBeijing GoBroad Boren Hospital
Dec 19, 2022
Asthma, COPD (COPD) Trial in Baltimore (CHF5993, CHF5259, Moxifloxacin 400mg)
Recruiting
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- CHF5993
- +3 more
-
Baltimore, MarylandPAREXEL Baltimore Early Phase Clinical Unit
Apr 13, 2023
QTc Interval Trial in Overland Park (Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose)
Recruiting
- QTc Interval
- Psilocybin
- +2 more
-
Overland Park, KansasAltasciences Clinical Kansas, Inc
Jul 26, 2022
Cardiac Repolarization in Healthy Subjects Trial in Tempe (TD-4208 175 mcg, TD-4208 700 mcg, Placebo for TD-4208)
Completed
- Cardiac Repolarization in Healthy Subjects
- TD-4208 175 mcg
- +3 more
-
Tempe, ArizonaCelerion
Feb 22, 2022
Hyperuricemia, Gout, Qt Interval, Variation in Trial in Austin (LC350189 200mg, Placebo, Moxifloxacin 400mg)
Completed
- Hyperuricemia
- +2 more
- LC350189 200mg
- +3 more
-
Austin, TexasPPD
Dec 15, 2021
Cough, Endometriosis, Overactive Bladder Trial in Mannheim (BAY1817080, Moxifloxacin, Placebo)
Completed
- Cough
- +2 more
- BAY1817080
- +2 more
-
Mannheim, Baden-Württemberg, GermanyCRS Clinical Research Services Mannheim GmbH
Jan 19, 2022
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection Trial in Overland Park (AZD0914, Moxifloxacin, Placebo)
Completed
- Electrocardiogram Repolarisation Abnormality
- Gonococcal Infection
- AZD0914
- +2 more
-
Overland Park, KansasVince and Associates Clinical Research
Mar 26, 2020
TQT Study Trial in Tempe (Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Moxifloxacin 400mg, Placebo for Tebipenem
Completed
- TQT Study
- Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo
- +3 more
-
Tempe, ArizonaCelerion
Mar 12, 2020
Healthy Volunteers Trial in London (MD1003, Moxifloxacin 400mg, Placebo for MD1003)
Unknown status
- Healthy Volunteers
- MD1003
- +3 more
-
London, Middlesex, United KingdomParexel Early Phase Clinical Unit London
Feb 19, 2020
Acinetobacter Baumannii-calcoaceticus Complex Infections Trial in Baltimore (ETX2514, Placebo, moxifloxacin)
Completed
- Acinetobacter Baumannii-calcoaceticus Complex Infections
- ETX2514
- +2 more
-
Baltimore, MarylandPharmaron Clinical Pharmacology Center
Aug 28, 2019
Healthy Volunteers Trial in Miami (CTP-543, Moxifloxacin, Placebo)
Completed
- Healthy Volunteers
- CTP-543
- +2 more
-
Miami, FloridaClinical Pharmacology of Miami, LLC
Feb 16, 2022
Healthy Subjects Trial in Phoenix (1.25 mg/kg BL-8040 + BL-8040-matching , 2 mg/kg BL-8040, BL-8040-matching )
Completed
- Healthy Subjects
- 1.25 mg/kg BL-8040 + BL-8040-matching placebo
- +3 more
-
Phoenix, ArizonaCelerion
Jan 1, 2023
Healthy Subjects Trial in Rennes (Combined oral contraceptives (COC), Moxifloxacin 400mg, Cenerimod 0.5 mg)
Completed
- Healthy Subjects
- Combined oral contraceptives (COC)
- +5 more
-
Rennes, FranceSite 1
Nov 15, 2022
Postoperative Pain Trial in London (SKY0402, Moxifloxacin 400mg, Placebo injection)
Completed
- Postoperative Pain
- SKY0402
- +3 more
-
London, United KingdomRichmond Pharmacology Ltd
Feb 11, 2021
Healthy Subjects Trial in New Haven (Venlafaxine, Moxifloxacin, Drug - )
Completed
- Healthy Subjects
- Venlafaxine
- +2 more
-
New Haven, ConnecticutPfizer New Haven Clinical Research Unit
Jan 26, 2021
Diabetes Trial in London (Moxifloxacin, hyper-glycaemic clamp)
Completed
- Diabetes
- Moxifloxacin
- hyper-glycaemic clamp
-
London, United KingdomRichmond Pharmacology Ltd. 1a Newcomen St, London Bridge
Apr 29, 2021
Cardiac Safety Trial in Belfast (telaglenastat, telaglenastat , moxifloxicin)
Completed
- Cardiac Safety
- telaglenastat
- +2 more
-
Belfast, Ireland, United KingdomCelerion
Mar 8, 2021
Healthy Trial in Dallas (CR845 0.5 mcg/kg IV, CR845 3 mcg/kg IV, Moxifloxacin 400 mg Oral Tablet)
Completed
- Healthy
- CR845 0.5 mcg/kg IV
- +3 more
-
Dallas, TexasCara Therapeutics Study Site
Feb 20, 2020